Compare Stocks: RNAZ, COYA, RANI, and GNLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.95 -0.8%	$4.78	$3.71 ▼ $7.75	$116.12M	0.58	154,529 shs	151,817 shs
GNLX Genelux	$2.56 +2.4%	$2.59	$2.29 ▼ $8.53	$115.83M	0.59	235,228 shs	154,650 shs
RANI Rani Therapeutics	$0.80 +0.9%	$0.82	$0.45 ▼ $3.87	$111.38M	0.69	575,800 shs	235,515 shs
RNAZ TransCode Therapeutics	$1.86 +8.8%	$2.39	$1.52 ▼ $15.94	$31.49M	1.25	50,726 shs	84,068 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-0.80%	+2.91%	+7.38%	-5.89%	-21.62%
GNLX Genelux	+2.40%	0.00%	+1.59%	-15.51%	-46.11%
RANI Rani Therapeutics	+0.88%	-1.46%	-4.88%	+16.27%	+63.03%
RNAZ TransCode Therapeutics	+8.77%	+18.47%	+4.49%	-78.94%	-87.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.95 -0.8%	$4.78	$3.71 ▼ $7.75	$116.12M	0.58	154,529 shs	151,817 shs
GNLX Genelux	$2.56 +2.4%	$2.59	$2.29 ▼ $8.53	$115.83M	0.59	235,228 shs	154,650 shs
RANI Rani Therapeutics	$0.80 +0.9%	$0.82	$0.45 ▼ $3.87	$111.38M	0.69	575,800 shs	235,515 shs
RNAZ TransCode Therapeutics	$1.86 +8.8%	$2.39	$1.52 ▼ $15.94	$31.49M	1.25	50,726 shs	84,068 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-0.80%	+2.91%	+7.38%	-5.89%	-21.62%
GNLX Genelux	+2.40%	0.00%	+1.59%	-15.51%	-46.11%
RANI Rani Therapeutics	+0.88%	-1.46%	-4.88%	+16.27%	+63.03%
RNAZ TransCode Therapeutics	+8.77%	+18.47%	+4.49%	-78.94%	-87.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	209.76% Upside
GNLX Genelux	2.80	Moderate Buy	$18.00	603.13% Upside
RANI Rani Therapeutics	2.83	Moderate Buy	$8.75	995.12% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNAZ, COYA, RANI, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	GNLX Genelux	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/26/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/21/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy
8/18/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$7.95M	14.61	N/A	N/A	$2.06 per share	2.40
GNLX Genelux	$10K	11,581.44	N/A	N/A	$0.30 per share	8.53
RANI Rani Therapeutics	$1.63M	68.33	N/A	N/A	$0.34 per share	2.35
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest RNAZ, COYA, RANI, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	RANI Rani Therapeutics	-$0.05	N/A	N/A	N/A	$1.28 million	N/A
11/4/2026	Q3 2026	GNLX Genelux	-$0.20	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	13.40	13.40
GNLX Genelux	N/A	2.39	2.39
RANI Rani Therapeutics	N/A	5.31	5.31
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
GNLX Genelux	37.33%
RANI Rani Therapeutics	30.19%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
GNLX Genelux	7.50%
RANI Rani Therapeutics	26.73%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
GNLX Genelux	26	45.24 million	41.85 million	Not Optionable
RANI Rani Therapeutics	69	139.40 million	102.14 million	Optionable
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable

RNAZ, COYA, RANI, and GNLX Headlines

Recent News About These Companies

TransCode Therapeutics (NASDAQ:RNAZ) Stock Jumps 12.1% - Still a Buy?

October 6, 2026 | americanbankingnews.com

TransCode Therapeutics Prepays $840,975 on Convertible Notes to Yorkville, Secures Waiver on Amortization Events

October 3, 2026 | kalkinemedia.comK

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

September 28, 2026 | prnewswire.com

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

September 22, 2026 | prnewswire.com

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

September 16, 2026 | seekingalpha.com

Join Today’s Live Investor Webinar with TransCode Therapeutics

September 16, 2026 | usatoday.com

TransCode Therapeutics Announces Leadership Transition

September 10, 2026 | prnewswire.com

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNAZ, COYA, RANI, and GNLX Company Descriptions

Coya Therapeutics NASDAQ:COYA

$4.95 -0.04 (-0.80%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.00 +0.05 (+1.01%)

As of 10/9/2026 07:51 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Genelux NASDAQ:GNLX

$2.56 +0.06 (+2.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 10/9/2026 07:30 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Rani Therapeutics NASDAQ:RANI

$0.80 +0.01 (+0.88%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.79 -0.01 (-1.25%)

As of 10/9/2026 07:30 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

TransCode Therapeutics NASDAQ:RNAZ

$1.86 +0.15 (+8.77%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.84 -0.02 (-1.29%)

As of 10/9/2026 07:30 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, COYA, RANI, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, COYA, RANI, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, COYA, RANI, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNAZ, COYA, RANI, and GNLX Company Descriptions

Coya Therapeutics NASDAQ:COYA

Genelux NASDAQ:GNLX

Rani Therapeutics NASDAQ:RANI

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNAZ, COYA, RANI, and GNLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNAZ, COYA, RANI, and GNLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNAZ, COYA, RANI, and GNLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNAZ, COYA, RANI, and GNLX Company Descriptions

Coya Therapeutics NASDAQ:COYA

Genelux NASDAQ:GNLX

Rani Therapeutics NASDAQ:RANI

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools